Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No	Ailment	Route	Dose Min	Dose Max	Unit	Dosage Form	Frequency	Additional Info
1	Dyspepsia	Oral	15	30	mg		o.d.	Dose: for 2 to 4 weeks
2	Gastro-oesophageal reflux disease	Oral	15	30	mg		o.d.	Dose: for 4 to 8 weeks; thereafter maintenance therapy can be continued with 15 or 30 mg once daily according to response
3	Erosive esophagitis	IV infusion	30		mg	Injection		Dose: for 7 days over 30 minutes daily is recommended
4	Peptic ulcer	Oral	30		mg		o.d.	Dose: Treatment is continued for 2 to 4 weeks for duodenal and 4 to 8 weeks for gastric ulcer
5	Eradication of H. pylori	Oral	30		mg		b.d.	Dose: combined with clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily or combined with clarithromycin 250 mg twice daily and metronidazole 400 mg twice daily; lansoprazole with amoxicillin and metronidazole has also been used
6	NSAIDS associated ulcer	Oral	30		mg			Dose: Given daily for 4 to 8 weeks.
7	Zollinger-ellison syndrome	Oral	60		mg		o.d.	Dose: adjusted as required. Doses of up to 90 mg twice daily have been used. Daily doses greater than 120 mg should be given in divided doses

Adult Dose

S.No	Ailment	Route	Dose Min	Dose Max	Unit	Dosage Form	Frequency	Additional Info
1	Dyspepsia	Oral	15	30	mg		o.d.	Dose: for 2 to 4 weeks
2	Gastro-oesophageal reflux disease	Oral	15	30	mg		o.d.	Dose: for 4 to 8 weeks; thereafter maintenance therapy can be continued with 15 or 30 mg once daily according to response
3	Erosive esophagitis	IV infusion	30		mg	Injection		Dose: for 7 days over 30 minutes daily is recommended
4	Peptic ulcer	Oral	30		mg		o.d.	Dose: Treatment is continued for 2 to 4 weeks for duodenal and 4 to 8 weeks for gastric ulcer
5	Eradication of H. pylori	Oral	30		mg		b.d.	Dose: combined with clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily or combined with clarithromycin 250 mg twice daily and metronidazole 400 mg twice daily; lansoprazole with amoxicillin and metronidazole has also been used
6	NSAIDS associated ulcer	Oral	30		mg			Dose: Given daily for 4 to 8 weeks.
7	Zollinger-ellison syndrome	Oral	60		mg		o.d.	Dose: adjusted as required. Doses of up to 90 mg twice daily have been used. Daily doses greater than 120 mg should be given in divided doses

Ref :-  Book : Martindale    Page : 1891   Edition : 37  

Pediatric Dose

Ref :- Book : Martindale    Page : 1892   Edition : 37  

►  Side Effect : Headache, Diarrhoea, Skin rashes, pruritus, Dizziness, Fatigue, Constipation, Nausea, Vomiting, Flatulence, Abdominal pain, Arthralgia, Myalgia, Urticaria, Erythematous rashes, Photosensitivity, Exfoliative dermatitis, Gastritis, Gastrointestinal tumours, Dry mouth, Bullous eruptions, Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Hypersensitivity reactions, Fever, Bronchospasm, Angioedema, Anaphylaxis, Pancytopenia, Insomnia, Somnolence, Vertigo, Reversible confusional states, Agitation, Depression, Hallucinations, Raised liver enzymes, Hepatitis, Jaundice, Hepatic failure, Hepatic encephalopathy
Ref :-   Book : Martindale    Page : 1891,1906   Edition : 37.  
►  Drug Interaction : Drug interaction of Lansoprazole is with Antacids,  Sucralfate , Atazanavir, Voriconazole , Itraconazole , Ketoconazole , Dasatinib, Warfarin , Phenytoin , Diazepam
Ref :-   Book : Martindale    Page : 1891,1908,1909   Edition : 37.  

Drug interaction

Drug Interaction : Drug interaction of Lansoprazole is with Antacids,  Sucralfate , Atazanavir, Voriconazole , Itraconazole , Ketoconazole , Dasatinib, Warfarin , Phenytoin , Diazepam

Book : Martindale    Page : 1891,1908,1909   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Lansoprazole and other proton pump inhibitors are metabolised by the cytochrome P450 system, primarily by isoenzyme CYP2C19, and to a smaller extent by CYP3A4. Inhibitors or inducers of these isoenzymes may affect exposure to lansoprazole and other proton pump inhibitors. In turn, proton pump inhibitors may alter the metabolism of some drugs metabolised by these enzymes. Lansoprazole may prolong the elimination of diazepam, phenytoin, and warfarin. Lansoprazole and other proton pump inhibitors can reduce the absorption of drugs such as dasatinib, ketoconazole, and itraconazole, whose absorption is dependent on an acid gastric pH. with voriconazole, the plasma concentration of both drugs may be increased. Other proton pump inhibitors may be similarly affected by voriconazole. Lansoprazole and other proton pump inhibitors should not be used with atazanavir, as it substantially reduces exposure to atazanavir. Antacids and sucralfate may reduce the bioavailability of lansoprazole, and should not be taken within 1 hour of a dose of lansoprazole.
Ref :-   Book : Martindale    Page : 1891,1908,1909   Edition : 37.  

Mechanism of Drug

Mechanism of Drug Drug Interaction : Lansoprazole and other proton pump inhibitors are metabolised by the cytochrome P450 system, primarily by isoenzyme CYP2C19, and to a smaller extent by CYP3A4. Inhibitors or inducers of these isoenzymes may affect exposure to lansoprazole and other proton pump inhibitors. In turn, proton pump inhibitors may alter the metabolism of some drugs metabolised by these enzymes. Lansoprazole may prolong the elimination of diazepam, phenytoin, and warfarin. Lansoprazole and other proton pump inhibitors can reduce the absorption of drugs such as dasatinib, ketoconazole, and itraconazole, whose absorption is dependent on an acid gastric pH. with voriconazole, the plasma concentration of both drugs may be increased. Other proton pump inhibitors may be similarly affected by voriconazole. Lansoprazole and other proton pump inhibitors should not be used with atazanavir, as it substantially reduces exposure to atazanavir. Antacids and sucralfate may reduce the bioavailability of lansoprazole, and should not be taken within 1 hour of a dose of lansoprazole.

Book : Martindale    Page : 1891,1908,1909   Edition : 37.  

►  Contraindication : Hepatic impairment
Ref :-   Book : Martindale    Page : 1891,1907   Edition : 37.  

  ►  Mechanism of Action :   Lansoprazole is a proton pump inhibitor. It suppresses secretion of gastric acid by inhibiting the enzyme system of hydrogen/potassium adenosine triphosphatase (H+/K+ ATPase), the ‘proton pump’ of the gastric parietal cell.
Ref :-   Book : Martindale    Page : 1891,1909   Edition : 37.  

►   Route of Elimination :   Hepatic (Metabolism), Renal, Faecal
Ref :-   Book : Martindale    Page : 1891   Edition : 37.  
►    Plasma Half-life :   Min value :-   1 hours,    Max value :-   2 hours.  
Ref :-   Book : Martindale    Page : 1891   Edition : 37.  
►    Peak Plasma Concentration :   Min value :-   1.5 hours,    Max value :-   2 hours.  
Ref :-   Book : Martindale    Page : 1891   Edition : 37.